Monitor for pipeline advancement updates, particularly the GABAB PAM program for substance use disorders and dipraglurant for brain injury recovery, as the new Head of Pharmaceutical Development may influence clinical timelines. The activist stake context (SC 13D/A filings by CEO Tim Dyer) and prior going-concern warning suggest potential for strategic actions, but this filing alone provides no catalyst.
Price Chart
Executive Summary
Addex Therapeutics announced executive management changes: Jean-Philippe Rocher appointed Head of Pharmaceutical Development, while Mikhail Kalinichev stepped down to focus on Neurosterix. This is a routine organizational change with no financial data or material business impact, occurring against a backdrop of activist stake accumulation by CEO Tim Dyer and a prior going-concern warning.
Key Facts
- Jean-Philippe Rocher appointed Head of Pharmaceutical Development and member of Executive Management, effective October 2, 2026.
- Mikhail Kalinichev stepped down as Head of Translational Science to focus on his role at Neurosterix.
- Dr. Rocher previously served at Addex and most recently retired as Head of Pharmaceutical Development at Neurosterix.
- No financial figures, revenue, earnings, or guidance were provided in the filing.
- The filing references regaining rights to the GABAB PAM program from Indivior but provides no financial terms or timeline.
Financial Impact
No financial impact disclosed; executive management changes with no associated costs or revenue implications.
Risk Factors
- Key personnel departure (Kalinichev) may slow translational science efforts.
- No financial data provided; company remains in a cash-constrained position per prior 20-F filing (CHF 1.6M cash, going concern).
- Activist stake accumulation by CEO could signal internal pressure, but no specific actions announced.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006345 |
| Exhibit: exh_991.htm | 0001171843-26-006345 |
| Document: 0001171843-26-006345-index-headers.html | 0001171843-26-006345 |
| Document: 0001171843-26-006345-index.html | 0001171843-26-006345 |
| Document: 0001171843-26-006345.txt | 0001171843-26-006345 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.18 | awaiting T+60 | — | $2.90 (−8.81%) |
Oct 2, 2026 24d ago | 6-K | $3.07 | awaiting T+60 | — | $2.90 (−5.54%) |
Sep 28, 2026 28d ago | 6-K | $2.81 | awaiting T+60 | — | $2.90 (−3.20%) |
Sep 25, 2026 4w ago | 6-K | $3.65 | awaiting T+60 | — | $2.90 (−20.55%) |
Aug 26, 2026 8w ago | 6-K | $4.23 | awaiting T+60 | — | $2.90 (+31.44%) |
Jul 8, 2026 15w ago | 6-K | $5.89 $2.98 | ▼ −49.41% | ▼ −51.90% | $2.90 (−50.76%) |
Jun 30, 2026 16w ago | 6-K | $5.70 $3.45 | ▲ +39.47% | ▲ +42.29% | $2.90 (+49.12%) |
Jun 25, 2026 17w ago | 6-K | $5.94 $3.40 | ▲ +42.76% | ▲ +46.49% | $2.90 (+51.18%) |
May 15, 2026 23w ago | 20-F | $6.83 $5.95 | ▲ +12.88% | ▲ +17.74% | $2.90 (+57.54%) |
Apr 23, 2026 26w ago | 6-K | $6.14 $5.60 | ▼ −8.79% | ▼ −13.81% | $2.90 (−52.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers